Cargando…
T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
We present a case of a 54‐year‐old male with multiple myeloma (MM) who presented with widespread pruritic erythematous lesions following ixazomib treatment. This occurred after his third cycle of treatment with ixazomib, thalidomide and dexamethasone and was controlled by potent steroids and tempora...
Autores principales: | Haq, M., Reyal, Y., Tiffin, N., Szakacs, S., Ferguson, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060122/ https://www.ncbi.nlm.nih.gov/pubmed/35663138 http://dx.doi.org/10.1002/ski2.57 |
Ejemplares similares
-
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma
por: Sampat, Parth J., et al.
Publicado: (2021) -
Cutaneous Pseudolymphoma Secondary to Facial Thread Lift Procedure
por: Makhecha, Meena, et al.
Publicado: (2019) -
Pseudolymphoma tattoo-induced
por: Pasolini, Giorgio, et al.
Publicado: (2011) -
Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016) -
Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)